Targeted therapy is estimated at 39.0% by treatment type in 2026, with advanced cholangiosarcoma at 43.0% and hospitals at 42.0%. Adoption depends on timely molecular testing, yet rare biomarker groups and demanding reimbursement evidence restrict broader treatment access.
Cholangiosarcoma Market Analysis By ApplicationCholangiosarcoma Market Analysis By Distribution ChannelCholangiosarcoma Market Analysis By Drug ClassCholangiosarcoma Market Analysis By End UserCholangiosarcoma Market Breakdown By Treatment Type, Application, And RegionCholangiosarcoma Market Opportunity Matrix Growth Vs Value